公司介绍：卓正医疗成立于2012年，是中国领先的私立中高端综合医疗服务机构，专注服务中高端医疗 市场，以大众富裕人群为核心目标客户。公司通过集中化、标准化及数字化管理系统，构建了覆盖中国 经济发达城市的服务网络，截至最后实际可行日期，在中国拥有19家医疗服务机构（含17家诊所及2家 医院），并在新加坡运营4家全科诊所、马来西亚运营1家全科诊所。采用家庭医疗模式，整合实体与线 上服务，提供儿科、齿科、眼科、皮肤科、耳鼻喉及外科、妇科、内科等多专科服务，强调循证医学原 则与全人医疗理念，通过跨科室协作满足患者家庭全生命周期健康需求，建立了实体与线上一体化的医 疗服务体系。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 来源：新 ...

雷递网 雷建平 12月17日 卓正医疗控股有限公司（简称："卓正医疗"）日前通过上市聆讯，准备在港交所上市。 卓正医疗2025年前8个月营收为6.96亿元，期内利润为8321万元。 8个月营收为6.96亿 卓正医疗于2012年在深圳创立，采用在线、线下一体化服务的新模式，在北京、上海、广州、深圳、成都、重庆、武汉、长沙、苏州、杭州等城市运营近30 家物理网点。 卓正医疗的服务涵盖内科及全科、外科、妇产科、儿科、齿科、皮肤科及医学美容、眼科、耳鼻喉科、个性化体检、日间手术、航空转运、国际转诊等多个 类别。 自2024年1月至3月，卓正医疗收购了武汉神龙天下合共51.04%股权，武汉神龙天下拥有武汉北斗星儿童医院及两家武汉诊所。武汉神龙天下已自2024年3月 28日起成为卓正医疗的非全资附属公司。 招股书显示，卓正医疗2022年、2023年、2024年营收分别为4.73亿、6.9亿、9.59亿元；毛利分别为4398万元、1.34亿元、2.26亿元；经营亏损分别为1.37亿、 6693万、4688万元；期内利润分别为-2.22亿、-3.53亿元、8023万元。 | | | 截至12月31日止年度 | | 截至8月3 ...

(文/解红娟 编辑/张广凯） 连续两次IPO折戟让卓正医疗的上市耐心备受考验，为规避2026年底对赌协议到期的风险，这家私立医疗机 构正在紧锣密鼓推进第三次IPO闯关。 近日，卓正医疗再度向港交所递交招股书，由海通国际与浦银国际担任联席保荐人。根据弗若斯特沙利文的 资料，以2024年的收入计，卓正医疗是中国第三大私立中高端综合医疗服务机构，市场份额为2.0%。 在此之前，卓正医疗上市征程已两度遇挫。回溯上市历程，卓正医疗首次闯关始于2024年5月16日，根据港交 所"招股书递交后6个月未完成上市流程自动失效"的规则，该份招股书于当年11月16日按期失效，首次IPO宣 告折戟。2025年3月18日，卓正医疗卷土重来递交第二份招股书，但同样因未能在6个月有效期内完成流程， 于9月18日再度失效。 距离第二份招股书失效不到两个月，卓正医疗再次提交招股书。而卓正医疗之所以对冲刺IPO如此急迫，或 许与前置投资者的对赌协议约束有关。 有媒体报道，招股书明确显示，授予IPO前投资者的赎回权已于本公司首次提交IPO日期前暂停。根据日期为 2025年3月17日的股东协议，仅在本公司的IPO被撤回、拒绝或失效；或2026年12 ...

Group 1 - ST Jingfeng (000908) will be subject to delisting risk warning starting October 23, 2025, due to the acceptance of a reorganization application by the Changde Intermediate People's Court [1] - The stock will be renamed to "*ST Jingfeng" with a daily price fluctuation limit of 5%, and it will be suspended for one day on October 22, 2025 [1] - As of the end of 2023, ST Jingfeng reported negative net assets and faced liquidity issues, leading to overdue bonds and previous delisting risk warnings [1] Group 2 - Yushu Technology has completed the first phase of its IPO guidance work, with the report published on the CSRC website detailing the progress [3][5] - The guidance period started on July 18, 2025, and aims to improve corporate governance and operational standards [5] - Yushu Technology plans to submit its IPO application documents between October and December 2025, with relevant operational data to be disclosed at that time [6] Group 3 - The Yushu Robotics concept stocks have shown strong performance this year, with an average price increase of 71.37%, significantly outperforming the Shanghai Composite Index [7] - Notable stocks include Zhejiang Rongtai, Wolong Electric Drive, and Zhongdali De, with year-to-date price increases of 316.38%, 240.73%, and 202.54% respectively [8] - Companies like Aobi Zhongguang-UW have reported positive earnings forecasts, benefiting from advancements in the 3D vision perception industry and expanding application scenarios [9]

Core Viewpoint - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical is a significant development, although her lack of experience in listed company secretary roles raises questions about her suitability for the position [3][6]. Company Overview - Luoxin Pharmaceutical, founded in 1988, has a diverse product range covering various medical fields including gastrointestinal diseases, pediatrics, oncology, and more [6]. - The company has experienced significant performance fluctuations in recent years, primarily due to the impacts of the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [6]. Financial Performance - For the first half of 2025, Luoxin Pharmaceutical reported a revenue of 1.077 billion, a decrease of 14.45% year-on-year, while achieving a net profit attributable to shareholders of 17.695 million, marking a turnaround from losses in the previous year [6][7]. - The total revenue for the latest reporting period was 1.077 billion, with a total cost of 1.098 billion, resulting in an operating profit of 39.41 million, which is a 133.12% increase year-on-year [7]. - The net profit attributable to the parent company's shareholders was 17.695 million, reflecting a 119.95% increase compared to the same period last year [7]. Management Background - Jiang Ying, the newly appointed Secretary of the Board, has a strong academic background with dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [3][5]. - Prior to her appointment, Jiang Ying worked in various roles at Guotai Junan Securities, Everbright Pramerica Fund, and Guotai Fund, but lacks experience in listed company secretary positions [3][5].

Group 1 - Distinct Healthcare Holdings Limited plans to issue up to 6.371 million shares for overseas listing on the Hong Kong Stock Exchange [1][3] - The company submitted its prospectus on March 18, 2025, with Haitong International and Ping An International as joint sponsors [3] - Established in 2012, the company operates 20 medical service institutions across 11 cities in China and 3 general clinics in Singapore [3] Group 2 - According to Frost & Sullivan, Distinct Healthcare is the third-largest private high-end comprehensive healthcare service provider in China by revenue, holding a market share of 1.7% as of 2023 [3] - The company ranks first among private high-end healthcare service providers in China based on the number of cities covered as of the end of 2023 [3] - It ranks second in terms of paid patient visits among all private high-end healthcare service providers in China [3]

Core Insights - The company reported a revenue of 2.87 billion in 2024, a year-on-year increase of 0.96%, and a net profit attributable to shareholders of 500 million, a year-on-year increase of 0.2% [1] - In Q1 2025, the company achieved a revenue of 740 million, a year-on-year increase of 5.1%, and a net profit attributable to shareholders of 180 million, a year-on-year increase of 6.2% [1] Revenue Breakdown - The revenue from planting reached 530 million, accounting for 19.4% of total revenue, with a year-on-year increase of 10.6% [1] - Orthodontics generated revenue of 470 million, accounting for 17.3% of total revenue, with a year-on-year decrease of 5.1% [1] - Pediatric services generated revenue of 500 million, accounting for 18.3% of total revenue, with a year-on-year increase of 0.3% [1] - Restoration services generated revenue of 460 million, accounting for 16.9% of total revenue, with a year-on-year increase of 1.5% [1] - Comprehensive services generated revenue of 760 million, accounting for 28.0% of total revenue, with a year-on-year increase of 1.3% [1] Profitability Metrics - The overall gross margin for medical services in 2024 was 39.3%, reflecting a decline of 0.09 percentage points compared to 2023 due to factors such as centralized procurement of dental implants and consumer downgrade [1] Expense Management - The company maintained good control over expense ratios, with a 2024 expense ratio of 15.8%, an increase of 0.2 percentage points year-on-year [2] - In Q1 2025, the expense ratio was 13.5%, with a sales expense ratio of 0.9%, management expense ratio of 9.8%, R&D expense ratio of 1.6%, and financial expense ratio of 1.2% [2] - The company has implemented various digital operations and AI technologies to enhance overall operational efficiency [2] Earnings Forecast - The expected EPS for 2025, 2026, and 2027 are projected to be 1.13, 1.20, and 1.28 respectively [3]